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Abstract
Botulinum neurotoxins (BoNTs) are counted among the most toxic substances known and
are responsible for human botulism, a life-threatening disease characterized by flaccid
muscle paralysis that occurs naturally by food poisoning or colonization of the gastrointes-
tinal tract by BoNT-producing clostridia. To date, 7 serologically distinct serotypes of BoNT
(serotype A-G) are known. Due to the high toxicity of BoNTs the Centers for Disease Con-
trol and Prevention (CDC) have classified BoNTs as category A agent, including the six
biological agents with the highest potential risk of use as bioweapons. Well tolerated anti-
bodies neutralizing BoNTs are required to deal with the potential risk. In a previous work,
we described the development of scFv and scFv-Fc (Yumab) from macaque origin
(Macaca fascicularis) neutralizing BoNT/A and B by targeting the heavy and light chain of
each serotype. In the present study, we humanized the macaque antibodies SEM120-
IIIC1 (anti-BoNT/A light chain), A1HC38 (anti-BoNT/A heavy chain), BLC3 (anti-BoNT/B
light chain) and B2-7 (anti-BoNT/B heavy chain) by germline-humanization to obtain a bet-
ter potential immunotolerance in humans. We increased the Germinality Index (GI) of
SEM120-IIIC1 to 94.5%, for A1HC38, to 95% for BLC3 and to 94.4% for B2-7. Further-
more, the neutralization efficacies of the germline-humanized antibodies were analyzed in
lethal and non-lethal in vivomouse assays as full IgG. The germline-humanized IgGs
hu8SEM120-IIIC1, hu8A1HC38, hu8BLC3 and hu8B2-7 were protective in vivo, when
anti-heavy and anti-light chain antibodies were combined. The synergistic effect and high
PLOSONE | DOI:10.1371/journal.pone.0161446 August 25, 2016 1 / 19
a11111
OPEN ACCESS
Citation: Miethe S, Mazuet C, Liu Y, Tierney R,
Rasetti-Escargueil C, Avril A, et al. (2016)
Development of Germline-Humanized Antibodies
Neutralizing Botulinum Neurotoxin A and B. PLoS
ONE 11(8): e0161446. doi:10.1371/journal.
pone.0161446
Editor: Jinny L Liu, Naval Research Laboratory,
UNITED STATES
Received: June 8, 2016
Accepted: August 7, 2016
Published: August 25, 2016
Copyright: © 2016 Miethe et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding:We acknowledge funding from the
European Community’s Seventh Framework Program
(FP7/2007-2013) under agreement no. 241832
granted to the AntiBotABE project. LFB
Biotechnologies provided support in the form of
salaries for authors RU and A. Fontayne, but did not
have any additional role in the study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. The specific roles of
humanness of the selected IgGs makes them promising lead candidates for further clinical
development.
Introduction
Botulism is a life-threatening disease associated with foodborne poisoning caused by intoxica-
tion with botulinum neurotoxins (BoNTs) that are produced by the spore-forming bacteria
Clostridium botulinum and certain other Clostridium spp. or by colonization of the gastrointes-
tinal tract by BoNT-producing clostridia. An intoxication with BoNT is characterized by flac-
cid and life-threatening muscle paralysis that requires long term treatment in an intensive care
unit [1,2]. BoNT are grouped in 7 serologically distinct serotypes (A to G). In 2014, a new sero-
type H was proposed [3,4], but further analysis indicates that it is a hybrid-like BoNT contain-
ing regions of similarity of BoNT/A1 and BoNT/F5 and was completely neutralized by
serotype A antitoxin [5]. Four BoNT serotypes (A, B, E and rarely F) are responsible for most
cases of human botulism [6]. Several cases of botulism, caused by BoNT/A, B and E, have been
reported [7–11], but only 1% of all food poisoning-related cases of botulism, including adult
toxin coinfections, are associated with BoNT/F [12]. BoNTs are type A-B heteromeric mole-
cules first produced as 150 kDa single-chain protoxins, which are subsequently activated by
proteolytic cleavage to generate a disulfide bond-linked structure containing a 50 kDa light
chain and a 100 kDa heavy chain. The heavy chain contains two functional domains (HC and
HN). These domains are required for toxin uptake into nerve cells by receptor-mediated endo-
cytosis (HC) and for the translocation of the light chain across the membrane into the neuronal
cytosol (HN) [13]. The toxicity of BoNTs is due to the catalytic domain of the light chain (a
zinc endopeptidase), which cleaves specific components of the SNARE complex (soluble N-
ethylmaleimide-sensitive factor attachment protein receptor) involved in the fusion of the syn-
aptic vesicle with the presynaptic membrane, including VAMP (vesicle-associated membrane
protein or synaptobrevin), SNAP25 (synaptosomal associated protein of 25 kDa) and Syntaxin
[13]. BoNTs are classified as category A agents by the Centers for Disease Control and Preven-
tion (CDC) due to their high toxicity. They belong to the group of six biological agents with the
highest risk of potential to be used as bioweapons [14,15]. Iraq was weaponizing BoNTs during
1990/91 Gulf war and the Japanese cult Aum Shinrikyo attempted to use BoNT for bioterror-
ism [16,14,17]. In several scenarios, a risk deliberate contamination of the food supply chain by
BoNTs has been highlighted [18]. The high biological relevance of BoNTs utilization as bio-
weapon requires the development of highly effective therapies. Antibodies represent significant
drugs for the treatment of a multitude of pathogens and toxins. The current approach for treat-
ment of botulism includes passive immunization with equine antitoxin sera consisting of Fab
and/or F(ab')2 preparations [19]. Unfortunately, equine sera may cause serious adverse effects,
including serum sickness and hypersensitivity [20]. This factor is particularly of concern for
treatment of infant botulism. Therefore, in case of infant botulism human polyclonal anti-bot-
ulinum immunoglobulin preparations are used, such as BabyBig1 [21]. The quantity of these
human preparations is limited and expensive [22]. The current situation illustrates the impor-
tance for new human-like or human antibodies that are highly effective and better tolerated
than common equine antibody preparations or more available in case of human immunoglob-
ulin preparations. In our previous studies, we described the development of neutralizing
human-like scFv-Fc against the light and heavy chains of BoNT/A and B [23–25]. However,
for future medical applications optimal tolerance in humans has to be ensured for these
Germline Humanized IgG Anti-BoNT/A+B
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antibodies. Several humanization methods have been described [26]. One method especially
for antibodies derived from non-human primates (NHP), called germline-humanization, is
based on the modification of the NHP antibody framework regions (FR) to increase the level of
identity with FRs encoded by the closest human germline gene sequences [27]. It is postulated
that human germline FR, as part of IgM antibodies, are better tolerated by the immune system
than FR sequences derived from IgG antibodies, which carry somatic hypermutations resulting
from affinity maturation and probably forms immunogenic sequences [28,29]. Due to the high
similarity of NHP and human antibodies, tools such as IMGT/V-QUEST can be used for iden-
tification of the human germline genes (V, (D), J), which are most similar to the sequence
encoding by the NHP variable regions. Differences in the amino acid sequences are determined
by the Germinality Index (GI) as a predictor of tolerance. The germline-humanization of
35PA83, an antibody of macaque origin neutralizing anthrax toxin in a pre-clinical develop-
ment, led to an increase of the GI (from 87.6% to 97.7%), which is higher than GI of the fully
human Fab 83K7C (GI 91.9%) used as a benchmark for this study [30]. Furthermore, the anti-
body WO-2 against Aβ peptide, associated with Alzheimer's disease, was successfully human-
ized by germline-humanization, retaining the affinity and ability to inhibit aggregation and
oligomer-mediated toxicity [31].
In this article, we describe the germline-humanization of the four NHP antibodies
SEM120-IIIC1 (anti-BoNT/A light chain) [24], A1HC38 (anti-BoNT/A heavy chain) [25],
BLC3 (anti-BoNT/B light chain) and B2-7 (anti-BoNT/B heavy chain) [23] and their in vivo
protection characteristics against BoNT/A and B when expressed as IgGs.
Results
Comparison between macaque anti-botulinum toxin antibodies and the
most similar corresponding human germline genes
In our previous studies, we reported the generation of neutralizing macaque scFv and scFv-Fc
against BoNT/A and BoNT/B: SEM120-IIIC1 (anti-BoNT/A light chain), A1HC38 (anti-
BoNT/A heavy chain), BLC3 (anti-BoNT/B light chain), B2-7 (anti-BoNT/B heavy chain) [23–
25]. The comparison of the macaque VH and VL with the human germline genes was per-
formed using IMGT/V-QUEST tool. The human germline genes most similar to the genes
encoding the four anti-BoNT antibodies are given in Table 1. The Germinality Index (GI) for
VH and VL of the macaque antibodies were calculated using IMGT/DomainGapAlign and
provided an indication of the identity between framework regions of the antibodies and those
encoded by the most similar human germline genes, as a percentage (Table 1). The differences
of the amino acid (AA) sequence between SEM120-IIIC1, A1HC38, BLC3 and B2-7 framework
regions and those coded by the most similar human germline genes were evaluated. In total, 23
AA (SEM120-IIIC1) and 27 AA (A1HC38) of the eight framework regions (180 AA) differed
from those of the selected human germline gene segments. Twenty-three out of the 180 resi-
dues of the eight framework regions differed from BLC3 and those of the selected human
Table 1. Human germline genesmost similar to the genes encoding the four anti-BoNT antibodies and the corresponding GI value.
Toxin Antibody VH VL GI [%]
V D J V J VH VL
A1 LC SEM120-IIIC1 IGHV1-8*02 IGHD3-22*01 IGHJ4*02 IGKV1–39*01 IGKJ3*01 86.6 87.6
HC A1HC38 IGHV5-a*04 IGHD1-26*01 IGHJ5*02 IGKV1-39*01 IGKJ3*01 83.3 86.5
B2 LC BLC3 IGHV4-28*06 IGHD5-12*01 IGHJ4*02 IGKV1-12*01 IGKJ2*01 86.8 87.6
HC B2-7 IGHV4-59*02 IGHD1-14*01 IGHJ5*02 IGKV1-33*01 IGKJ4*01 84.6 77.3
doi:10.1371/journal.pone.0161446.t001
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germline gene segments. In the case of B2-7, 34 of the 179 residues of the FRs differed from the
selected human germline gene segments with highest homology (Fig 1).
Based on the physicochemical classes of the amino acids, differences in the FRs were classi-
fied as very similar, similar, dissimilar and very dissimilar AA according to IMGT [32]. For VH
of SEM120-IIIC1, we identified three residues classified as similar AA, four residues as dissimi-
lar AA and five residues as very dissimilar AA. For VL, one residue was classified as very simi-
lar AA, five as similar AA, two as dissimilar AA and three as very dissimilar AA. In the case of
A1HC38 (VH), we identified one residue classified as very similar AA, five as similar AA, three
residues as dissimilar AA and six residues as very dissimilar AA. For VL, one residue was classi-
fied as very similar AA, three as similar AA, three as dissimilar AA and five as very dissimilar
AA. For VH of BLC3, we identified three residues classified as similar AA, three as dissimilar
AA and six as very dissimilar AA. For VL, one residue was classified as very similar AA, five as
similar AA, two as dissimilar AA and three as very dissimilar AA. For VH of B2-7, one residue
was identified as very similar AA, four as similar AA, three as dissimilar AA and six as very dis-
similar AA. For VL, we identified ten residues as similar AA, five as dissimilar AA and five as
very dissimilar AA (Fig 1).
Germline-humanization of the macaque antibodies
In a first step towards humanization we exchanged the AA in the FRs of SEM120-IIIC1,
A1HC38, BLC3 and B2-7 with their human counterpart classified as very similar AA and simi-
lar AA. The resulting humanized variable domains were called hu1VH and hu1VL. Further-
more, we included the AA classified as dissimilar AA resulting in the humanized variants
hu2VH and hu2VL. In the case of SEM120-IIIC1, we decided to exchange the AA classified as
Fig 1. Sequence of the macaque framework regions and those coded by the most similar human germline genes. Based on the
physiochemical classes of the amino acids (AA), differences in the framework regions are classified into very similar AA (green), similar
AA (blue), dissimilar AA (orange) and very dissimilar AA (red).
doi:10.1371/journal.pone.0161446.g001
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very dissimilar AA resulting in the humanized Variants hu3VH and hu3VL and modeled each
variant using WAM antibody modeling [33]. The resulting structures of the respective human-
ized domains of SEM120-IIIC1 were compared with the determined parental structure of VH
and VL (Figs 2 and 3). For VH, after exchange of the similar AA we observed a structural
change of CDR3. Detailed analyses indicated that the exchange of leucine to valine in FR1
(V21>L) was responsible for this effect (Fig 2A and 2B). By retaining the parental AA at this
position (hu1VH/V21>L) and further modifications including dissimilar AA and very dissimi-
lar AA no significant changes of the structure were observed in the calculated structure model.
In the next step, each humanized variable domain was combined with each other including the
parental VH and VL and produced as scFv-Fc. The humanized variants of the resulting anti-
bodies were termed hu1SEM120-IIIC1 up to hu16SEM120-IIIC1 (Table 2).
The antigen binding of the 16 humanized variants was compared and validated by ELISA
using immobilized recombinant light or heavy chain of BoNT and by surface plasmon reso-
nance (SPR) analyses using holotoxin. Based on the results of the ELISA and SPR analyses we
selected hu8SEM120-IIIC1 for further in vivo studies (Fig 4, Table 3). This humanized anti-
body with a total GI value of 94.5% was generated by adapting the 4 FR regions of the light
chain to the most similar human germline genes, resulting in a GI value of 100% for VL. For
VH (GI 89%), only 2 similar AAs were exchanged compared to the most similar human
Fig 2. 3D structure of the humanized VH variants. A) Comparison hu1VH (red) vs. SEM120-IIIC1 (black). B) Comparison hu1VH/
V21>L (blue) vs. SEM120-IIIC1 (black). C) Comparison hu2VH/V21>L (green) vs. SEM120-IIIC1 (black). D) Comparison hu3VH/V21>L
(orange) vs. SEM120-IIIC1 (black).
doi:10.1371/journal.pone.0161446.g002
Fig 3. 3D structure of the humanized VL variants. A) Comparison hu1VL (blue) vs. SEM120-IIIC1 (black). B) Comparison hu2VL
(turquoise) vs. SEM120-IIIC1 (black). C) Comparison hu3VL (green) vs. SEM120-IIIC1 (black).
doi:10.1371/journal.pone.0161446.g003
Germline Humanized IgG Anti-BoNT/A+B
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germline genes. Hu8SEM120-IIIC1 has nearly the same affinity (1.41 nM) against the holo-
toxin compared to the parental antibody (0.82 nM). The exchange of the dissimilar AA and
very dissimilar AAs in the heavy chain of SEM120-IIIC1 led to a reduction of antigen binding.
The effect of the AAs which were not exchanged in hu8SEM120-IIIC1 were observed by single
back-mutations and tested by ELISA neutralization in the mouse phrenic nerve-hemdiaph-
ragm ex vivo studies [24]. The mutation of leucine to valine in FR1 (V21>L) resulted in reduc-
tion of toxin neutralization efficiency (data not shown) compared to hu8SEM120-IIIC1 which
is in accordance with the structure model. Furthermore, single mutations of dissimilar AA or
very dissimilar AAs located in VH reduced the antigen binding of the humanized anti-BoNT/
A light chain antibody.
Based on the results of the humanization of SEM120-IIIC1, for the germline-humanization
of A1HC38, BLC3 and B2-7 we only used very similar, similar and dissimilar AA exchanges.
The resulting humanized antibody variants were named hu1A1HC38 up to hu8A1HC38,
hu1BLC3 up to hu8BLC3 or hu1B2-7 up to hu8B2-7 (Table 4). The antigen binding of the
eight humanized variants of A1HC38, BLC3 and B2-7 was compared and validated by ELISA
using recombinant light and heavy chain of BoNT/A or B (S1, S2 and S3 Figs). Based on these
results, we decided to use hu8A1HC38, hu8BLC3 and hu8B2-7 variants for further in vivo
studies.
Table 2. GI value of the humanized variants of the different humanized variants of SEM120-IIIC1 and A1HC38.
Variant VH Variant VL Variant Total GI
SEM120-IIIC1 macaque VH macaque VL 87.2%
hu1SEM120-IIIC1 macaque VH macaque VL 87.2%
hu2SEM120-IIIC1 macaque VH hu1VL 90.6%
hu3SEM120-IIIC1 macaque VH hu2VL 91.7%
hu4SEM120-IIIC1 macaque VH hu3VL 93.4%
hu5SEM120-IIIC1 hu1VH/V21>L macaque VL 88.3%
hu6SEM120-IIIC1 hu1VH/V21>L hu1VL 91.7%
hu7SEM120-IIIC1 hu1VH/V21>L hu2VL 92.8%
hu8SEM120-IIIC1 hu1VH/V21>L hu3VL 94.5%
hu9SEM120-IIIC1 hu2VH/V21>L macaque VL 90.5%
hu10SEM120-IIIC1 hu2VH/V21>L hu1VL 93.9%
hu11SEM120-IIIC1 hu2VH/V21>L hu2VL 94.9%
hu12SEM120-IIIC1 hu2VH/V21>L hu3VL 96.7%
hu13SEM120-IIIC1 hu3VH/V21>L macaque VL 93.3%
hu14SEM120-IIIC1 hu3VH/V21>L hu1VL 96.7%
hu15SEM120-IIIC1 hu3VH/V21>L hu2VL 97.8%
hu16SEM120-IIIC1 hu3VH/V21>L hu3VL 99.5%
Variant VH Variant VL Variant Total GI
A1HC38 macaque VH macaque VL 84.4%
hu1A1HC38 macaque VH hu1VL 87.4%
hu2A1HC38 macaque VH hu2VL 89.1%
hu3A1HC38 hu1VH macaque VL 88.3%
hu4A1HC38 hu1VH hu1VL 90.5%
hu5A1HC38 hu1VH hu2VL 92.2%
hu6A1HC38 hu2VH macaque VL 89.9%
hu7A1HC38 hu2VH hu1VL 92.2%
hu8A1HC38 hu2VH hu2VL 94.9%
doi:10.1371/journal.pone.0161446.t002
Germline Humanized IgG Anti-BoNT/A+B
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By performing germline-humanization we increased the GI of SEM120-IIIC1 to 94.5% and
to 94.9% for A1HC38, to 95% for BLC3 and to 94.4% for B2-7 (Tables 2 and 4).
Production of germline-humanized IgG
The full length cDNA coding each pair of heavy and light chains were obtained by fusing by
PCR assembly VH and VK with the human IgG1 and κ constant regions respectively. These
sequences were then introduced into the expression vector HKgenEFss by Infusion. The YB2/0
cell line was transfected with the resulting constructs to generate stable pools for production in
roller bottles. The culture supernatants were harvested, concentrated and filtered. The antibod-
ies were then purified by affinity chromatography on Sepharose protein A followed by sterile
Fig 4. Antigen ELISA of the humanized variants of SEM120-IIIC1 against recombinant light chain of BoNT/A1. Binding of the
germline-humanized anti-BoNT/A1 antibodies (hu1-hu16SEM120-IIIC1) as scFv-Fc (each 1 μg) was tested on 100 ng recombinant
BoNT/A1 light chain.
doi:10.1371/journal.pone.0161446.g004
Table 3. Affinity measurement of the humanized SEM120-IIIC1 variants as scFv-Fc against holotoxin
BoNT/A1 (no affinities for hu9-hu16, no reactivity).
variant koff [s
-1] kon [M
-1s-1] KD [nM]
SEM120-IIIC1 6.87 x 10−5 8.34 x 104 0.82
hu1SEM120-IIIC1 1.14 x 10−4 1.09 x 105 1.04
hu2SEM120-IIIC1 1.07 x 10−4 1.06 x 105 1.02
hu3SEM120-IIIC1 2.14 x 10−4 1.07 x 105 1.99
hu4SEM120-IIIC1 1.48 x 10−4 1.64 x 105 0.89
hu5SEM120-IIIC1 1.09 x 10−4 6.35 x 104 1.71
hu6SEM120-IIIC1 8.31 x 10−5 5.73 x 104 1.45
hu7SEM120-IIIC1 2.27 x 10−4 1.18 x 105 1.92
hu8SEM120-IIIC1 1.33 x 10−4 9.41 x 104 1.41
doi:10.1371/journal.pone.0161446.t003
Germline Humanized IgG Anti-BoNT/A+B
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filtration. The purified antibodies were considered pure by SDS-PAGE. Aggregates and endo-
toxin contaminations were monitored by SEC and LAL assay respectively. The detected quanti-
ties were below 5 IU/mg of endotoxin and 0.7% of aggregates making the use of these
antibodies compatible with in vivo evaluation.
In vivo protection (paralysis assays)
The selected IgGs targeting BoNT/A light chain (hu8SEM120-IIIC1) and heavy chain
(hu8A1HC38) were tested in vivo in the mouse flaccid paralysis protection model both individ-
ually, and in combination for synergistic effect against pure BoNT/A1 (0.4 LD50 per dose, 1.74
pg) toxin. Results from observation of animals after 48 h are presented in Fig 5A. Complete
protection was achieved with 100 μg, 50 μg and 10 μg per dose of hu8A1HC38, targeting the
heavy chain of BoNT/A1 toxin, whereas partial protection was observed at all lower doses
tested (5 μg and 1 μg per dose). However, hu8SEM120-IIIC1, targeting the light chain of
BoNT/A1 did not fully protect against the paralysis induced by BoNT/A1 toxin, even at 100 μg
of IgG per dose (Fig 5A). In fact all doses of antibody between 100 μg and 5 μg provided similar
protective effect with no benefit of dose increase. Additional reduction in protection was seen
when the dose of IgG was further reduced to 1 μg per dose. When these two IgGs, were com-
bined as mixture (hu8SEM120-IIIC1 and hu8A1HC38) full protection was observed at all
doses used. The lowest dose where animals remained fully protected from paralysis was 0.1 μg
of each IgG (0.2 μg total IgG), whereas full protection was not observed at 1.0 μg of individual
antibody, confirming synergistic effect (Fig 5A).
The selected IgGs targeting the BoNT/B light chain (hu8BLC3) and heavy chain (hu8B2-7)
were also tested individually and in combination for synergistic effect against paralysis induced
by complex BoNT/B2 (0.2 LD50 per dose). Results for 48 hr after intoxication are presented in
Fig 5B. Complete protection was achieved with hu8BLC3 at 100 μg, 50 μg and 10 μg per dose
and partial protection with two further 10-fold dilutions (Fig 5B). Antibody hu8B2-7 did not
Table 4. GI value of the humanized variants of the different humanized variants of BLC7 and B2-7.
Variant VH Variant VL Variant Total GI
BLC3 macaque VH macaque VL 87.2%
hu1BLC3 macaque VH hu1VL 90.6%
hu2BLC3 macaque VH hu2VL 91.7%
hu3BLC3 hu1VH macaque VL 88.9%
hu4BLC3 hu1VH hu1VL 92.3%
hu5BLC3 hu1VH hu2VL 93.4%
hu6BLC3 hu2VH macaque VL 90.5%
hu7BLC3 hu2VH hu1VL 93.9%
hu8BLC3 hu2VH hu2VL 95.0%
Variant VH Variant VL Variant Total GI
B2-7 macaque VH macaque VL 81.0%
hu1B2-7 macaque VH hu1VL 86.1%
hu2B2-7 macaque VH hu2VL 89.5%
hu3B2-7 hu1VH macaque VL 83.7%
hu4B2-7 hu1VH hu1VL 88.8%
hu5B2-7 hu1VH hu2VL 92.2%
hu6B2-7 hu2VH macaque VL 85.9%
hu7B2-7 hu2VH hu1VL 91.0%
hu8B2-7 hu2VH hu2VL 94.4%
doi:10.1371/journal.pone.0161446.t004
Germline Humanized IgG Anti-BoNT/A+B
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significantly protect mice at any of the concentrations used in this study from 100 μg to 0.1 μg
per dose. However, the combination of hu8B2-7 and hu8BCL3 fully protected mice in vivo at
0.25 μg dose of each IgG (0.5 μg total IgG) where protection was not observed for each anti-
body alone at 1.0 μg dose.
Positive control group of mice received a single injection of either BoNT/A1 (0.4 LD50 per
dose) or BoNT/B2 (0.2 LD50 per dose) where a mean score of approximately 3 was observed in
both studies (Fig 5). Negative control group of mice (n = 4) was injected with 100 μg of IgG
mixtures (50 μg of each IgG) in the absence of toxin and did not show any local effect (data not
shown).
In vivo protection (lethal assays)
To further investigate the in vivo neutralizing potency of the antibodies, the selected IgGs tar-
geting BoNT/A light chain (hu8SEM120-IIIC1) and heavy chain (hu8A1HC38) were tested in
vivomouse lethality both individually and in combination for synergistic effect against com-
plexed form of BoNT/A1 using 5x mouse 50% lethal doses (5 MLD50) per mouse (Table 5).
Although partial protection was achieved with 25 μg and 2.5 μg of hu8SEM120-IIICI or 2.5 μg
of hu8A1HC38, respectively, complete neutralization of BoNT/A1 lethal activity was obtained
by combining both antibodies. The lowest fully protective dose was 2.5 μg of each IgG (5 μg
total IgG), whereas 25 μg of individual antibody only induced a partial protection or survival,
but with strong symptoms of botulism intoxication (hu8A1HC38), thus confirming the syner-
gistic effect between the two antibodies (Table 5). When the dose was further reduced tenfold
(0.25 μg of each IgG), 50% protection in mice was still observed (Table 5). The selected IgGs
Fig 5. Protection capacities of IgGs. In vivomouse paralysis assay was performed to determine protection capacities of IgGs
targeting BoNT/A (5A) or BoNT/B (5B) light and heavy chains. A) Pure BoNT/A1 (0.4 LD50 per dose, 1.74 pg) was pre-mixed with
either hu8SEM120-IIIC1 (light chain) or hu8A1HC38 (heavy chain) at 100 μg, 50 μg, 10 μg, 5 μg or 1 μg of antibody per dose. When
tested in combination IgGs (hu8SEM120-IIIC1 and hu8A1HC38 50) were pre-mixed with the same concentration of BoNT/A1 and 50 μg,
10 μg, 2.5 μg, 1.0 μg, 0.25 μg or 0.1 μg of each antibody per dose (100 μg, 20 μg, 5.0 μg, 2.0 μg, 0.5 μg or 0.2 μg total IgG). B) Complex
BoNT/B2 (0.2 LD50 per dose) was pre-mixed with either hu8BLC3 (light chain) or hu8B2-7 (heavy chain) at 100 μg, 10 μg, 1 μg or 0.1 μg
per dose. When tested in combination IgGs (hu8BLC3 and hu8B2-7) were pre-mixed with the same concentration of BoNT/B2 and 50 μg
or 0.25 μg of each antibody per dose (100 μg or 0.5 μg total IgG). In both studies mixtures of toxin and antibody were left for 30 min at
room temperature before 0.1 mL was injected subcutaneously into left inguinocrural region of female MF1 strain of mice (n = 4). Animals
were scored at 48 hr post injection. Results are expressed as mean score of 4 mice ± SEM. Positive control group of mice received a
single injection of either BoNT/A1 (0.4 LD50 per dose) or BoNT/B2 (0.2 LD50 per dose). In each study negative control comprised of one
group of mice (n = 4) injected with the highest concentration of IgG mixtures (50 μg each) without toxin (data not shown).
doi:10.1371/journal.pone.0161446.g005
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targeting the BoNT/B light chain (hu8BLC3) and heavy chain (hu8B2-7) were also tested indi-
vidually and in combination for synergistic effect against lethality induced by complex BoNT/
B2 (approximately 5 MLD50/mouse). The results for BoNT/B2 were quite similar to those
obtained with antibodies against BoNT/A1 (Table 6): partial protection was achieved with
doses of 25 μg and 2.5 μg of hu8BLC3 (anti-BoNT/B light chain) and no protection or
extremely weak protection with the same doses of hu8B2-7 (anti-BoNT/B heavy chain) tested
individually. However, the combination of hu8B2-7 and hu8BLC3 fully protected mice in vivo
at 2.5 μg dose of each IgG (5 μg total IgG). Further reduced doses (0.25 μg of each IgG) still
induced 50% protection against 5 MLD50 of BoNT/B2 (Table 6).
Discussion
In previous studies, neutralizing macaque antibodies were generated against BoNT/A. The anti-
BoNT/A1 antibody SEM120-IIIC1 isolated from a macaque immune library inhibited the endo-
peptidase activity of BoNT/A1 in vitro with a molar ratio of 5:1 (antibody binding:toxin) as
scFv-Fc and neutralized BoNT/A1 toxicity in the ex vivomouse phrenic nerve-hemidiaphragm
assay by targeting the light chain of BoNT/A1 [24]. The scFv A1HC38 targeting the heavy chain
of BoNT/A1 was highly effective in the ex vivomouse phrenic nerve-hemidiaphragm assay, that
mimics the in vivo respiratory paralysis caused by BoNTs [25]. The antibodies BLC3 and B2-7
respectively targeting the light and heavy chain of BoNT/B2, were isolated from immune librar-
ies. The scFv-Fc (Yumab) format of these antibodies neutralized BoNT/B2 toxicity in the ex vivo
mouse phrenic nerve-hemidiaphragm assay. Both scFv-Fc in combination were highly effective
in the in vivomouse flaccid paralysis assay, where complete protection against BoNT/B2 (0.2
LD50 per mouse) was achieved [23]. The high “humanness” of all four antibodies predicts a high
tolerance in human. Studies with the chimeric antibody lumiliximab, consisting of the variable
regions of a macaque in combination with the human constant regions, showed a good immune
tolerance in human subjects [34,35]. Nevertheless, the germline-humanization of these antibod-
ies provides a potentially promising method for increasing immune tolerance for human
Table 6. Protection capacities of IgGs in in vivomouse assay. Neutralization potencies of hu8BLC3 and hu8B2-7, tested individually or in combination,
against 5 MLD50 of BoNT/B2 in complex form. The preparations of antibodies and toxin (0.5 mL) were injected intraperitoneally into Swiss mice (20–22 g).
The results are expressed as the number of the surviving mice of the total number of mice injected.
Antibody BoNT/B2 (strain BL6, complexed form)
5 MLD50/mice (survival mice/total mice)
hu8BLC3 hu8B2-7 Combination
25 μg/mice 6/8 1/4 8/8
2.5 μg/mice 5/8 0/4 8/8
0.25 μg/mice 0/4 2/4 5/8
doi:10.1371/journal.pone.0161446.t006
Table 5. Protection capacities of IgGs in in vivomouse assay. Neutralization potencies of hu8SEM120-IIIC1 and hu8A1HC38, tested individually or in
combination, against 5 MLD50 of BoNT/A1 in complex form. The preparations of antibodies and toxin (0.5 mL) were injected intraperitoneally into Swiss mice
(20–22 g). The results are expressed as the number of the surviving mice of the total number of mice injected.
Antibody BoNT/A1 (strain HALL)
5 MLD50/mice (survival mice/total mice)
hu8SEM120-IIIC1 hu8A1HC38 Combination
25 μg/mice 1/4 4/4 (4 very symptomatic) 8/8
2.5 μg/mice 3/4 2/4 8/8
0.25 μg/mice 0/4 1/4 4/8
doi:10.1371/journal.pone.0161446.t005
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treatment [27]. This method was successfully used for the humanization of 35PA38, an antibody
neutralizing the anthrax lethal toxin isolated from a macaque immune library which is currently
in clinical development as IgG, where GI value was increased to 97.8% [30]. For comparison,
the average GI value of 95.7% was calculated for 500 scFvs isolated from the human naïve anti-
body gene library HAL7/8 [36]. The number of differences between the framework regions of
the macaque SEM120-IIIC1 and those encoded by the closest human germline genes was 23,
resulting in a GI value of 87.2%, whereas 27 different AA were identified in the framework
regions of A1HC38 resulting in a GI value of 84.4%. For the anti-BoNT/B antibodies, 23 AA
(BLC3) and 34 AA (B2-7) were identified in the FRs that differs from the closest human germ-
line genes, resulting in a GI value of 87.2% (BLC3) and 81% (B2-7).
These differences could either correspond to somatic hypermutations or to differences
between the macaque and human germline genes and both could be immunogenic. Therefore,
we decided to increase the GI value by a systematic approach. We adapted the FRs of
SEM120-IIIC1, A1HC38, BLC3 and B2-7 to the human counterparts, because the human
germline FRs as part of IgM antibodies should be as well tolerated as any other human protein,
in contrast to the FR sequences derived from IgG antibodies, which carry somatic hypermuta-
tions resulting from affinity maturation and probably forms immunogenic sequences [29,37].
For the humanization process dedicated to decrease immunogenicity of the four antibodies we
used a multistep approach. In the first step, we designed humanized variants of the variable
domains by exchanging the AA in the FRs that differ from the human germline sequence with
their human counterpart classified as very similar and similar AA. The resulting variable
domains were called hu1VH and hu1VL. In the next step we included the AA classified as dis-
similar AA, resulting in the humanized variants hu2VH and hu2VL and combined each vari-
able domain with each other including the parental VH and VL. In the case of SEM120-IIIC1
we additionally exchanged the very dissimilar AA (hu3VH and hu3VL). By exchanging these
AA, we were able to increase the GI value of the humanized antibodies up to 94.5% (hu8SE-
M120-IIIC1), 94.9% (A1HC38), 95% (hu8BLC3) and 94.4% (hu8B2-7).
For the humanized variants, only ten (hu8SEM120-IIIC1), eleven (hu8A1HC38), nine
(hu8BLC3) and eleven (hu8B2-7) AA of the parental antibody were retained in the frameworks.
The average GI of 500 scFv, isolated out of the naïve human antibody gene library HAL7/8, was
96.8% (VH), 95.4% (VL lambda) and 94.8% (VL kappa). With GI values of 95% (hu8BLC3),
94.4% (hu8B2-7), 94.5% (hu8SEM120-IIIC1) and 94.9% (hu8AHC38) the germline-humanized
variable domains are as human as naïve human germline derived variable domains.
The protective capacities of the four germline-humanized IgG, targeting the light and heavy
chains of BoNT/A and BoNT/B were evaluated initially in the mouse local flaccid paralysis
assay, which provides a less time consuming and more humane alternative to the LD50 assay
[38]. Evaluating for protection of mice against locally induced toxin effect was considered a
first step towards validation of protection capacities of selected IgGs. Whereas scFv-Fc against
BoNT/B were previously tested in mouse paralysis assay in vivo [23], similar studies were not
performed with scFv or scFv-Fc targeting BoNT/A light [24] or heavy chains [25], which were
only evaluated for toxin neutralization properties in the mouse phrenic nerve-hemidiaphragm
assay ex vivo on tissue isolated from mice. The studies confirmed that IgG hu8A1HC38 at
10 μg per dose fully protected mice from paralysis whereas hu8SEM120-IIIC1 did not protect,
even at 100 μg dose. In combination, these two antibodies at as low as 0.1 μg each (0.2 μg total
IgG) per dose fully protected mice from paralysis induced by 0.4 LD50, (1.74 pg) of toxin which
increased the ratio of protection by at least 100-fold.
In agreement to our previous observation using scFv-Fc preparations of BLC3 and B2-7
[23], we confirmed that IgG hu8B2-7 alone, even at 100 μg, did not protect mice from paralysis
induced by 0.2 LD50 of BoNT/B2, whereas IgG hu8BLC3 at 10 μg did confer protection.
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In case of the anti-BoNT/B2 antibodies we made an interesting observation. We expected
that the main protective effect against BoNTs based on the binding of the heavy chain, which is
responsible for receptor binding and translocation of the light chain into the cytoplasm. The
protective effect of the anti-light chain antibody hu8BLC3 could be caused by binding an epi-
tope close to the heavy chain that interacts with receptor binding or inhibits the translocation
of the light chain into the cytoplasm. It is also possible that hu8BLC3 still blocking the endo-
peptidase activity of the light chain in the cytoplasm.
Furthermore, in agreement to previous observations with scFv-Fc, combination of IgG also
exhibited synergistic protection in mice when each IgG was given at 0.25 μg per dose (0.5 μg
total IgG). Results obtained in the mouse lethality test corroborated neutralization property of
individual selected antibodies obtained in the mouse phrenic nerve- hemi diaphragm ex vivo
assay and/or in the local flaccid paralysis mouse assay [23–25]. Where a partial protection was
achieved with doses of 25 μg and 2.5 μg of anti-BoNT/A light chain (hu8SEM120-IIIC1) or
anti-BoNT/A heavy chain (hu8A1HC38) tested individually, complete neutralization of the
lethal activity induced by 5 MLD50 of BoNT/A1 was obtained by combining the two antibodies
at 2.5 μg each (5 μg total IgG). Similarly, we observed a protective synergistic effect of antibod-
ies directed against the heavy chain (hu8B2-7) and light chain (hu8BLC3) of BoNT/B down to
the dose of 2.5 μg (5 μg total IgG against 5 MLD50 BoNT/B). Both lethal and paralysis assays in
mice established that full protection against 1 LD50 of either BoNT/A or BoNT/B can be
achieved with 1 μg of two IgGs in combination. The demonstration of the protective synergistic
effect is in agreement with results obtained with an oligoclonal recombinant antibody prepara-
tion composed of 3 mAbs directed against BoNT/A [39] and with the combination of two
mAbs directed against BoNT/A HC and the LC domains [40]. However, single mAbs or
recombinant chimeric counterparts have been proved to be very efficient in neutralizing
BoNT/A activity in the mouse protection assay without additional antibodies [41–43]. A com-
bination of the four germline-humanized anti-BoNT/A and B IgGs with a formerly described
anti-BoNT/E antibody [44] would result in a promising oligoclonal antibody product that
could be effective against the three most important BoNTs.
In combination of the germline-humanized IgG targeting the HC and LC domain of BoNT/A
and B are neutralizing in vivo and it is expected that these IgGs are well tolerated in humans with
less or no adverse effect. In contrast to usual therapeutics, such as BabyBig1 or HBAT, they can
be produced in large amount without the use of animals and are suitable for further clinical
development as part of an oligoclonal drug for treatment of botulism. Such a drug would be help-
ful both for the European Union biodefense and for the treatment of natural botulism.
Materials and Methods
Ethical statements and animal care
The in vivo local flaccid paralysis assay was performed at NIBSC by an approved procedure
covered by the UK Home Office project license (PPL#80/2634, granted to Dr. Sesardic) which
covered research under AntiBotABE project. The procedure involves administration subcuta-
neously into mice of sub-lethal doses of BoNT premixed with antibody for neutralization stud-
ies, and observation for signs of abdominal ptosis with local palsy in mice over a period of 48
hr at the site of injection. None of the animals experience systemic botulinum toxicity in this
procedure [38]. All such experiments comply with the UK Home Office regulations for the use
of animals in research under Animals (Scientific Procedures) Act 1986 (ASPA) and revised
European Directive 2010/63 EU on the protection of animals. Experiments performed at
NIBSC for this study were approved by the local animal research oversight committee AWERB
(Animal Welfare and Ethics Review body).
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The in vivomouse lethality test was performed at Institut Pasteur in accordance with French
and European Community guidelines for laboratory animal handling. The protocols of experi-
ments were approved by the Institut Pasteur (Agreement of laboratory animal use n° 2013–
0118). Mice were kept at a constant temperature (22°C ±2°C) and relative humidity (50%),
with 12 hr of artificial light per day. They were housed in individual cages (8 per room). Mice
were fed with dried food and water at libitum. Mice were observed every two hours post-injec-
tion except during the night from 7 pm to 7 am, over a period of 4 days. The animals with char-
acteristic symptoms of botulism including muscle paralysis, respiratory difficulty were
euthanized by cervical dislocation. No unexpected death (death in non symptomatic animals)
was observed.
Humanization of the macaque antibodies by germline-humanization
The sequence of each antibody was compared with the human germline genes using the
IMGT/V-QUEST online tool from the International ImmunoGeneTics information system1
(IMGT) (http://www.imgt.org). This tool allows identification of the human germline genes
most similar to any given variable region and calculates the Germinality Index (GI), defined as
the percentage identity between a given framework region (FR) and the most similar human
germline sequence. Based on the physiochemical classes of the amino acids (AA), differences
in the FRs were classified as very similar, similar, dissimilar and very dissimilar AA. Firstly,
humanized variants of VH and VL were designed by exchanging the very similar AA and simi-
lar AA followed by dissimilar AA and very dissimilar AA. The structure of each domain was
modeled using WAM antibody modeling [33] and visualized using UCSF Chimera software
[45]. The humanized VH and VL genes were synthesized by GeneArt1 Gene Synthesis
(Regensburg, Germany) and were used for expression of scFv-Fc and IgG.
Production and purification of scFv-Fc antibodies
All humanized variants were subcloned into pCSE2.5-mIgG2c-Fc-XP and produced as scFv-Fc
antibody in HEK293-6E cells (National Research Council (NRC), Biotechnological Research
Institute (BRI)) cultured in chemically defined medium F17 (Thermo Fisher Scientifics, Wal-
tham, USA) supplemented with 1 g/L pluronic F68 (Applichem, Darmstadt, Germany), 4 mM
L-glutamine (Biochrom GmbH, Berlin, Germany) and 25 mg/L G418 (Biochrom GmbH, Ber-
lin, Germany), as previously described [46]. The scFv-Fc produced were chimeric macaque-
mouse antibodies. DNA was used for the transient transfection of 25 mL cultures of HEK293-
6E cells in 125 mL Erlenmeyer shake flasks. After 48 hr of culture with shaking at 110 rpm in a
Minitron orbital shaker (Infors GmbH, Einsbach, Germany) at 37°C, under an atmosphere
containing 5% CO2, one volume of culture medium, with a final concentration of 0.5% (w/v)
tryptone N1 (TN1, Organotechnie S.A.S., La Courneuve, France), scFv-Fc were purified on a
UNOsphere SUPrA column (Biorad, Hercules, USA) with a Profinia apparatus (Biorad, Her-
cules, USA), according to the manufacturer’s instructions.
Cloning of germline-humanized IgG
The different germline-humanized IgGs were constructed and expressed as described previ-
ously [47]. Briefly, the DNA sequences for variable and constant regions for heavy and light
chains were obtained by PCR and sub-cloned sequentially by Infusion into HKgenEFss vector.
This generic vector is developed for an optimal expression into the rat myeloma cell line YB2/
0. Bacterial transformation was performed in E. coli Top10 cells (Thermo Fisher Scientifics,
Waltham, USA) for each plasmid ligation in order to select the ligated product and amplifica-
tion. Positive clones were selected by PCR and digestion on individual colonies was performed.
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Subsequently, colonies were grown overnight at 37°C in LB medium with ampicillin. Plasmids
were isolated using the NucleoSpin kit (Macherey-Nagel, Berlin, Germany), and inserted
sequences were verified (MWG, Ebersberg, Germany).
Production and purification of germline-humanized IgG
The stable expression of the humanized antibody was obtained as previously described [47].
Briefly, YB2/0 were stably transfected with the linearized expression vectors. The humanized
IgGs were produced in YB2/0 over 5 to 7 days using EMS (Invitrogen, Carlsbad, USA), 5%
Ultra low IgG FCS (PAA) and 0.5 g/L G418. The antibodies were purified from culture super-
natant by affinity chromatography onto protein A sepharose (GE-Healthcare, Chalfont St
Giles, UK). The level of aggregates and endotoxins were determined by gel filtration on Super-
dex HR/200 (GE-Healthcare, Chalfont St Giles, UK) and by LAL (limulous amoebocyte lysate)
testing [48], respectively. Antibody quality and purity was also monitored by SDS-PAGE and
Coomassie staining. In addition, glycosylation patterns and the core fucose percentage were
determined for each purified antibody by high performance capillary electrophoresis laser
induced fluorescence (HPCE-Lif) [49,50] confirming the EMABling characteristic.
ELISA analyses
ELISA was performed in 96-well microtiter plates (Corning, New York, USA). Each well was
coated with recombinant light or heavy chain of BoNT/A or B (100 ng per well) (ListLabs,
Campbell, UK), in 100 μL of phosphate-buffered saline (PBS) by incubating overnight at 4°C.
The coated wells were washed three times with PBST (PBS + 0.05% Tween 20) using an ELISA
plate washer (Tecan Columbus, Tecan, Männedorf, Switzerland). The wells were then blocked
by incubation with 2% (w/v) skimmed milk powder in PBS supplemented with 0.1% Tween 20
(2%M-PBST) for 1 hr at room temperature, and then washed three times with PBST. For the
antigen ELISA with scFv-Fc antibodies, the humanized variants of SEM120-IIIC1, BLC3 and
B2-7 were diluted in 100 μL of 2% M-PBST and incubated in the antigen-coated wells for 1 hr
at room temperature. The wells were then washed three times with PBST. Bound scFv-Fc were
detected with a peroxidase-labeled goat anti-mouse antibody recognizing the murine part of
the Fc fragment (A0168, Sigma-Aldrich). In case of A1HC38, the antigen ELISA was per-
formed with scFv phage particles. The humanized variants of A1HC38 were diluted in 100 μL
of 2% M-PBST and incubated in the antigen-coated wells. After 1 hr incubation at room tem-
perature, the wells were washed three times with PBST. Bound scFv phage particles were
detected with mouse anti-pIII antibody (PSKAN3, MoBiTec) and a peroxidase-labeled goat
anti-mouse antibody (A0168, Sigma-Aldrich). Afterwards, antigen binding was visualized in a
detection reaction with TMB (3,3’,5,5’-tetramethylbenzidine) as the substrate. The staining
reaction was stopped by adding 100 μL of 1 N sulfuric acid. Absorbance at 450 nm (reference
wavelength: 620 nm) was measured in a SUNRISE™microtiter plate reader (Tecan, Männedorf,
Switzerland).
Affinity measurement
The affinity of the germline-humanized antibodies were measured by surface plasmon reso-
nance (SPR) with a Biacore X instrument (GE-Healthcare, Chalfont St Giles, UK). Each anti-
body (1000 resonance units [RU]) was immobilized on a CM5 chip via amine coupling,
according to the manufacturer’s instruction. A flow rate of 30 μL/min was adjusted and six
dilutions of BoNT (0.16 μM to 5 nM in HBS-EP buffer) were tested. After each measurement,
the chip was regenerated for 30 s with glycine-HCl (pH 1.5) at a flow rate of 10 μL/min. The
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affinity of the antibodies was calculated with Biaevaluation software [51] and checked in inter-
nal consistency tests [52].
In vivo neutralization studies in mouse flaccid paralysis assay
Protection capacities of selected IgGs was assessed in mouse flaccid paralysis assay as previ-
ously described [38] and were tested individually and in combination against BoNT/A1
(hu8SEM120-IIIC1 and hu8A1HC38) or BoNT/B2 (hu8BLC3 and hu8B2-7) serotypes of
toxin. Purified BoNT/A1 heamagglutinin-free holotoxin (Metabiologics Inc, Madison, Wi.
USA) was purchased with specific activity of 2.3 x 108 LD50/mg, and 0.4 LD50 (1.74 pg) was
used per dose. Botulinum B2 (BoNT/B2) complex toxin was prepared by Institut Pasteur
(Paris, France) with provided activity of 6.8 x 104 LD50/mg (total protein) and 0.2 LD50 was
used per dose. In both cases, the sub-lethal dose of toxin was selected from the previous studies
[53] as the highest dose of toxin inducing local flaccid paralysis within 48 hrs after subcutane-
ous injection into left inguinocrural region of mice. This selected dose (in range 0.2–0.4 LD50)
will not cause death or systemic symptoms of botulism. Selected antibodies were studied for
protection properties at four or five concentrations ranging from 100 μg to 0.1 μg per dose. For
the combination protocol two antibodies against the heavy and light chains of BoNT/A
(hu8SEM120-IIIC1 and hu8A1HC38) or BoNT/B (hu8BLC3 and hu8B2-7) were used at a
range of concentrations between 50 μg and 0.1 μg per dose of each IgG, and were pre-mixed
with the same dose of toxin. All dilutions were prepared in gelatin (0.2% w/v) phosphate (50
mM di-sodium hydrogen orthophosphate) buffer, (GPBS, pH 6.5), and toxin:antibody mix-
tures were left for 30 min at room temperature before injecting 0.1 mL subcutaneously into
female MF1 strain of mice, weighing between 16–20 g (n = 4 per dose). All injections were per-
formed within 30 min and all the mice were injected in the left inguinocrural region. Scores
were recorded at 48 hr post injection with intensity of paralysis ranging from 0, (no sign of
paralysis), to scores between 1 and 4, defined by an increasing extent of local flaccid paralysis.
Positive control group of mice were injected with BoNT/A1 or BoNT/B2 toxin alone, and
negative control group of mice were injected with the maximum concentration of each anti-
body (50 μg) used in the assay, in the absence of toxin. Assay was considered valid if positive
control group of mice showed visible local paralysis effect induced by selected dose of toxin
(with a mean score close to 3) and mice receiving highest dose of IgG preparations, in the
absence of toxin, did not show any visible paralytic effect.
In vivo protection (lethal assays)
The neutralizing activity of the antibodies was evaluated in the in vivomouse lethality test as
previously described [42]. Neutralization tests were performed using crude acid-precipitated
toxins from strain Hall (type A1) and strain BL6 (type B2) [23,54]. Toxin preparations were
diluted in 50 mM phosphate buffer pH 6.3 containing 0.2% gelatin (PB-G) and calibrated to
approximately 10x mouse 50% lethal doses (10 MLD50) per mL. Ten-fold and then two-fold
serial dilutions of antibodies in PB-G were incubated with 10 MLD50 of BoNT type A1 or B2
preparations for 30 min at room temperature. Afterwards, 0.5 mL of the mixtures (5 MLD50)
were injected by intraperitoneal route into Swiss male mice weighing 20–22 g. Groups of at
least 4 mice were used for each dilution. Mice were observed at regular intervals and any symp-
toms recorded every day for 4 days.
Supporting Information
S1 Fig. Titration ELISA of the humanized variants of A1HC38 against recombinant heavy
chain of BoNT/A1. Binding of the germline-humanized anti-BoNT/A1 antibodies
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(hu1-hu8A1HC38) as scFv phage (2.5x105 up to 5x108 cfu) was tested on 100 ng recombinant
BoNT/A1 heavy chain.
(TIFF)
S2 Fig. Titration ELISA of the humanized variants of BLC3 against recombinant light
chain of BoNT/B2. Binding of the germline-humanized anti-BoNT/B2 antibodies
(hu1-hu8BLC3) as scFc-Fc was tested on 100 ng recombinant BoNT/B2 light chain.
(TIFF)
S3 Fig. Titration ELISA of the humanized variants of B2-7 against recombinant heavy
chain of BoNT/B2. Binding of the germline-humanized anti-BoNT/B2 antibodies
(hu1-hu8B2-7) as scFc-Fc was tested on 100 ng recombinant BoNT/B2 heavy chain.
(TIFF)
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